Psoriasis is a chronic inflammatory skin disorder that, despite its non-life-threatening nature, has a major impact on patients’ quality of life. The growing use of biologics and increasing rates of drug treatment in moderate to severe psoriasis have resulted in a psoriasis market with multi-billion-dollar sales. The current landscape of the moderate to severe psoriasis market has been characterized by intense competition between the two tumor necrosis factor-alpha (TNF-α) inhibitors (Amgen/Stiefel/Pfizer’s Enbrel [etanercept] and AbbVie’s Humira [adalimumab]) as first-line biologics and the growing challenge of Janssen Biotech’s interleukin-12 and 23 (IL-12/23) inhibitor Stelara (ustekinumab) against TNF-α inhibitors’ entrenched dominance in the moderate to severe psoriasis market. Further intensifying the competition for patient share, several new agents are poised to enter the psoriasis market within the next two years, including two agents with the advantage of oral formulations (Pfizer’s Janus kinase (Jak) inhibitor Xeljanz [tofacitinib] and Celgene’s phosphodiesterase-4 [PDE-4] inhibitor apremilast), and efficacious IL-17 inhibitors (Novartis’s secukinumab and Eli Lilly’s ixekizumab). The expanding use of these premium-priced agents will likely strain healthcare budgets, and increasing payer restrictions on accessing prescription psoriasis drugs are expected.
Decision Resources’ Physician & Payer Forum report “Will the Anticipated Approval and Reimbursement of Novel Orals Result in a Major Shift in Biologics Prescribing in Psoriasis? U.S. Payer and Prescriber Attitudes Toward Novel Oral and Biologic Emerging Agents in the Psoriasis Market” explores the factors that shape current and future treatment patterns as well as reimbursement trends in psoriasis. Additionally, this report reveals dermatologist and payer perception of oral and biological therapies with a novel mechanism of action (MOA), which are expected to launch within two years, as well as biosimilar versions of infliximab and their impact on current therapy use. This report is based on a survey of 106 dermatologists and 31 pharmacy and medical directors (PDs and MDs) of managed care organizations (MCOs) that offer commercial health insurance and Medicare prescription drug plans.
Markets covered: United States.
Primary research: Online survey of 106 dermatologists and 31 MCO pharmacy or medical directors.
Epidemiology: 2012-2016 prevalent cases of psoriasis in the United States.
Market analysis: 2012 U.S. market and patient share by drug class.